A re-assessment of treatment with a tyrosine kinase inhibitor (imatinib) on tissue sparing and functional recovery after spinal cord injury

Experimental Neurology

Volumn 254, Issue , 2014, Pages 1-11

  Sharp, Kelli G ^a   Yee, Kelly Matsudaira ^a   Steward, Oswald ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Axon regeneration; BBB scale; Bladder function; Contusion injury; Gleevac ; Imatinib; Recovery of function; Spinal cord injury

Indexed keywords

IMATINIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER FUNCTION; BLOOD BRAIN BARRIER; CELL INVASION; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; FUNCTIONAL ASSESSMENT; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INVESTIGATIVE PROCEDURES; LOCOMOTION; MOLECULAR DYNAMICS; MOTOR PERFORMANCE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; RATING SCALE; SPINAL CORD INJURY; TASK PERFORMANCE; TISSUE CHARACTERIZATION; TISSUE PRESERVATION; TISSUE SPARING; URINALYSIS; URINE VOLUME; WHITE MATTER;

AXON REGENERATION; BBB SCALE; BLADDER FUNCTION; CONTUSION INJURY; GLEEVAC®; IMATINIB; RECOVERY OF FUNCTION; SPINAL CORD INJURY;

ANIMALS; BENZAMIDES; DISEASE MODELS, ANIMAL; FEMALE; HINDLIMB; MOTOR ACTIVITY; NERVE FIBERS, MYELINATED; NERVE REGENERATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECOVERY OF FUNCTION; REFLEX; SPINAL CORD INJURIES; URINARY BLADDER;

EID: 84893426649     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.12.019     Document Type: Article

References (16)

1. Abrams M.B., Nilsson I., Lewandowski S.A., Kjell J., Codeluppi S., Olson L., Eriksson U. Imatinib enhances functional outcome after spinal cord injury. PLoS One 2012, 7:e38760.
2. Anderson K.D. Targeting recovery: priorities of the spinal cord-injured population. J. Neurotrauma 2004, 21:1371-1383.
3. Basso D.M., Beattie M.S., Bresnahan J.C. A sensitive and reliable locomotor rating scale for open field testing in rats. J. Neurotrauma 1995, 12:1-21.
4. Boucher P., Gotthardt M., Li W.P., Anderson R.G., Herz J. LRP: role in vascular wall integrity and protection from atherosclerosis. Science 2003, 300:329-332.
5. David B.T., Steward O. Deficits in bladder function following spinal cord injury vary depending on the level of the injury. Exp. Neurol. 2010, 226:128-135.
6. Fabian M.A., Biggs W.H., Treiber D.K., Atteridge C.E., Azimioara M.D., Benedetti M.G., Carter T.A., Ciceri P., Edeen P.T., Floyd M., Ford J.M., Galvin M., Gerlach J.L., Grotzfeld R.M., Herrgard S., Insko D.E., Insko M.A., Lai A.G., Lelias J.M., Mehta S.A., Milanov Z.V., Velasco A.M., Wodicka L.M., Patel H.K., Zarrinkar P.P., Lockhart D.J. A small molecule-kinase interaction map for clinical kinase inhibitors. Nat. Biotechnol. 2005, 23:329-336.
7. Lassila M., Allen T.J., Cao Z., Thallas V., Jandeleit-Dahm K.A., Candido R., Cooper M.E. Imatinib attenuates diabetes-associated atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 2004, 24:935-942.
8. Leder C., Ortler S., Seggewiss R., Einsele H., Wiendl H. Modulation of T-effector function by imatinib at the level of cytokine secretion. Exp. Hematol. 2007, 35:1266-1271.
9. Metz G.A., Merkler D., Dietz V., Schwab M.E., Fouad K. Efficient testing of motor function in spinal cord injured rats. Brain Res. 2000, 883:165-177.
10. Norenberg M.D., Smith J., Marcillo A. The pathology of human spinal cord injury: defining the problems. J. Neurotrauma 2004, 21:429-440.
11. Paniagua R.T., Sharpe O., Ho P.P., Chan S.M., Chang A., Higgins J.P., Tomooka B.H., Thomas F.M., Song J.J., Goodman S.B., Lee D.M., Genovese M.C., Utz P.J., Steinman L., Robinson W.H. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 2006, 116:2633-2642.
12. Schwab M.E., Bartholdi D. Degeneration and regeneration of axons in the lesioned spinal cord. Physiol. Rev. 1996, 76:319-370.
13. Steward O., Popovich P.G., Dietrich W.D., Kleitman N. Replication and reproducibility in spinal cord injury research. Exp. Neurol. 2012, 233:597-605.
14. Su E.J., Fredriksson L., Geyer M., Folestad E., Cale J., Andrae J., Gao Y., Pietras K., Mann K., Yepes M., Strickland D.K., Betsholtz C., Eriksson U., Lawrence D.A. Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat. Med. 2008, 14:731-737.
15. Tator C.H., Fehlings M.G. Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J. Neurosurg. 1991, 75:15-26.
16. Zhang Y.P., Onifer S.M., Burke D.A., Shields C.B. A topical mixture for preventing, abolishing, and treating autophagia and self-mutilation in laboratory rats. Contemp. Top. Lab. Anim. Sci. 2001, 40:35-36.